TransDigm Group enters the summer lull trading near $1,257 — up 4.2% on the day and just shy of all-time highs — yet the options market is sending a notably cautious signal that sits in tension with the stock's strength.
The most pointed data point this week is the put/call ratio. Options positioning is far more defensive than usual: the PCR hit 2.77, well above its 20-day average of 2.14, and has held above 2.6 for the past ten sessions. The broader context makes this more striking — back in mid-May the PCR was barely above 0.5, the 52-week low. The rotation from calls to puts has been sharp and sustained. At 0.74 standard deviations above the mean, it doesn't yet register as statistically extreme, but the directional shift is hard to ignore as the stock grinds higher.
Short interest, by contrast, tells a quieter story. Bears hold roughly 1.9% of the free float — a level too modest to be the central narrative. What's notable is the trend: shorts built through the first two weeks of June after a multi-month low in mid-May, pushing the 30-day change to +6.3%. That said, the borrow market signals no stress. Cost to borrow is a negligible 0.42%, down 18% on the week. Availability is extremely loose at over 2,600% — meaning there are roughly 26 shares available to borrow for every one already lent out, close to the most accommodating level of the past year. Shorts rebuilding is a deliberate choice, not a forced trade.
The Street has a buy consensus, but the direction of recent analyst moves points to some trimming of ambition. After Q2 earnings on May 5 — when TDG jumped 7.3% on the day — UBS and Stifel both maintained Buy ratings while cutting targets meaningfully, to $1,645 and $1,525 respectively (from $1,745 and $1,650). RBC and Susquehanna trimmed to $1,350 with neutral-equivalent stances. The mean target of $1,524 still implies around 21% upside from current levels, but the post-earnings target cuts suggest the Street is recalibrating. The bull case centres on commercial OE demand growing at high single-to-mid-teens and a 160 basis point margin expansion. The bear case rests on the FY2026 EBITDA forecast of $5.15 billion coming in below expectations, with the newly acquired Simmonds business diluting margins by a projected 140 basis points year-over-year. On valuation, the trailing P/E is running near 29x and EV/EBITDA at 17.3x — neither cheap, though both have drifted up modestly over the past month as the stock has recovered. The ORTEX short score of 32.6 sits in the bottom half of the universe, consistent with a name where institutional conviction is firm and short pressure is light.
The ownership picture reinforces that institutional conviction. Capital Research and Management holds 24% of shares outstanding — an unusually concentrated anchor position — and added 333,000 shares in its most recent filing. BlackRock added 303,000 shares. The one notable counterweight is founder and Chairman Walter Howley, who sold roughly $6.6 million across a series of transactions on May 18, spread across multiple tranches between $1,145 and $1,189. The significance scores on each trade were low (rated 2 out of 10), suggesting these are routine programme sales rather than a conviction call. Close peers showed mixed action this week: LOAR gained 2.4% and SARO added 1.8%, broadly tracking TDG's direction, while BETA fell 11.3% — a divergence that likely reflects company-specific factors rather than a sector read-through.
With Q3 earnings not due until August 4, the next test for TDG is whether the defensive put positioning resolves as the stock holds its recent highs, or whether the gap between bullish analyst targets and cautious options positioning narrows from the other direction.
See the live data behind this article on ORTEX.
Open TDG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
